Latest REOLYSIN Stories

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the Cancer...

CALGARY, May 14, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 16(th), 2013 at 10:40 a.m. PT. The conference will take place from May 14(th) to May 16(th) at Encore at Wynn Las Vegas in  Las Vegas, NV. A live audio link to the webcast presentation is available at:...

CALGARY, May 10, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated April 4, 2013 were elected as directors at its 2013 Annual and Special Meeting of Shareholders, held on Thursday, May 9th, 2013. On a vote by ballot, the following nine nominees proposed by management were elected as Directors of Oncolytics to serve until the Company`s next Annual Meeting of Shareholders or until...

CALGARY, May 9, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2013. "We recently reported positive data from our squamous cell carcinoma of the lung study both with respect to the study's primary endpoint and tumour shrinkage, which supports the conduct of further studies in this indication," said Dr. Brad Thompson, President and...

CALGARY, April 29, 2013 /PRNewswire/ - Dr. Alan J. Tuchman, Senior Vice President, Medical & Clinical Affairs and Chief Medical Officer of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present a corporate overview of the Company at the 12(th) Annual Needham Healthcare Conference on Tuesday, April 30(th), 2013 at 12:10 p.m. ET. The conference will take place on April 30(th) and May 1(st) at the Westin Grand Central Hotel in New York, NY. A live audio link to the...

CALGARY, March 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC) (NASDAQ:ONCY) today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy...

CALGARY, March 14, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the  year ended December 31, 2012. "We were very pleased to present our first randomized clinical data from our head and neck cancer clinical study in 2012," said Dr. Brad Thompson, President and CEO of Oncolytics. "In addition, in order to support our program, which now includes seven...

CALGARY, March 5, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016). This trial is a single arm, single-stage, open-label, Phase 2 study of REOLYSIN given...

CALGARY, Feb. 25, 2013 /PRNewswire/ - Dr. Matt Coffey, Chief Operating Officer of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present at the 2013 RBC Capital Markets Healthcare Conference on Tuesday, February 26, 2013 at 3:35 p.m. ET. The conference will take place on February 26(th) and 27(th) in New York, NY. A live audio link to the webcast presentation is available at: http://www.veracast.com/webcasts/rbc/healthcare2013/71114328.cfm or on the company's website at...

CALGARY, Feb. 20, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC, NASDAQ: ONCY) today announced the appointment of Dr. Jeremy Grushcow to the role of General Counsel. Dr. Grushcow has more than ten years' experience in the legal profession representing public and private entities, as well as venture capital and private equity firms in the acquisition, financing, development, operation and sale of pharmaceutical and life sciences companies in...